Titre : Glucan 1,3-beta-glucosidase

Glucan 1,3-beta-glucosidase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Lymph Node Excision
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Glucan 1,3-beta-glucosidase : Questions médicales les plus fréquentes", "headline": "Glucan 1,3-beta-glucosidase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Glucan 1,3-beta-glucosidase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-18", "dateModified": "2025-05-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Glucan 1,3-beta-glucosidase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellulases", "url": "https://questionsmedicales.fr/mesh/D044602", "about": { "@type": "MedicalCondition", "name": "Cellulases", "code": { "@type": "MedicalCode", "code": "D044602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.277.450.420.200" } } }, "about": { "@type": "MedicalCondition", "name": "Glucan 1,3-beta-glucosidase", "alternateName": "Glucan 1,3-beta-Glucosidase", "code": { "@type": "MedicalCode", "code": "D043326", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Johannes Wagener", "url": "https://questionsmedicales.fr/author/Johannes%20Wagener", "affiliation": { "@type": "Organization", "name": "Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, Munich, Germany." } }, { "@type": "Person", "name": "Shigekazu Yano", "url": "https://questionsmedicales.fr/author/Shigekazu%20Yano", "affiliation": { "@type": "Organization", "name": "Graduate School of Sciences and Engineering, Yamagata University." } }, { "@type": "Person", "name": "Malgorzata Mikulska", "url": "https://questionsmedicales.fr/author/Malgorzata%20Mikulska", "affiliation": { "@type": "Organization", "name": "Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy." } }, { "@type": "Person", "name": "Malcolm Finkelman", "url": "https://questionsmedicales.fr/author/Malcolm%20Finkelman", "affiliation": { "@type": "Organization", "name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA." } }, { "@type": "Person", "name": "Yonglong Zhang", "url": "https://questionsmedicales.fr/author/Yonglong%20Zhang", "affiliation": { "@type": "Organization", "name": "Clinical Development, Associates of Cape Cod, Inc, Falmouth, MA, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Radiation, Lymph Node Dissection, or Both: Management of Lymph Node Micrometastases from Merkel Cell Carcinoma.", "datePublished": "2023-04-27", "url": "https://questionsmedicales.fr/article/37106277", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-13437-z" } }, { "@type": "ScholarlyArticle", "name": "Clinical outcomes of neoadjuvant therapy followed by selective inguinal lymph node dissection and total mesorectal excision for metastasized low rectal cancer.", "datePublished": "2022-12-28", "url": "https://questionsmedicales.fr/article/36577899", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00423-022-02739-7" } }, { "@type": "ScholarlyArticle", "name": "Robotic versus laparoscopic total mesorectal excision with lateral lymph node dissection for advanced rectal cancer: A systematic review and meta-analysis.", "datePublished": "2024-05-29", "url": "https://questionsmedicales.fr/article/38809911", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0304031" } }, { "@type": "ScholarlyArticle", "name": "Inguinal Lymph-Node Ratio (LNR) as a predictor of Pelvic Lymph-Node Metastasis in squamous cell carcinoma of penis.", "datePublished": "2023-06-08", "url": "https://questionsmedicales.fr/article/37315351", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.suronc.2023.101964" } }, { "@type": "ScholarlyArticle", "name": "Factors Associated With Lymph Node Yield and Effects of Lymph Node Density on Survival of Patients With Pulmonary Sarcomatoid Carcinoma.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36256867", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/COC.0000000000000946" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Hydrolases", "item": "https://questionsmedicales.fr/mesh/D006867" }, { "@type": "ListItem", "position": 5, "name": "Glycosidases", "item": "https://questionsmedicales.fr/mesh/D006026" }, { "@type": "ListItem", "position": 6, "name": "Glucosidases", "item": "https://questionsmedicales.fr/mesh/D005959" }, { "@type": "ListItem", "position": 7, "name": "Cellulases", "item": "https://questionsmedicales.fr/mesh/D044602" }, { "@type": "ListItem", "position": 8, "name": "Glucan 1,3-beta-glucosidase", "item": "https://questionsmedicales.fr/mesh/D043326" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Glucan 1,3-beta-glucosidase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Glucan 1,3-beta-glucosidase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Glucan 1,3-beta-glucosidase", "description": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?\nQuels tests sont utilisés pour mesurer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des marqueurs biologiques associés à cette enzyme ?\nComment les tests génétiques aident-ils au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Glucan 1,3-beta-glucosidase", "description": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?\nLa déficience peut-elle causer des problèmes immunitaires ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Glucan 1,3-beta-glucosidase", "description": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?\nY a-t-il des mesures préventives pour les symptômes ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation des patients est-elle importante ?\nLes conseils diététiques peuvent-ils prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Glucan 1,3-beta-glucosidase", "description": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des thérapies alternatives recommandées ?\nLa diététique joue-t-elle un rôle dans le traitement ?\nDes traitements expérimentaux sont-ils disponibles ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Glucan 1,3-beta-glucosidase", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle entraîner des infections fréquentes ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Glucan 1,3-beta-glucosidase", "description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque de déficience ?\nLes facteurs environnementaux influencent-ils le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs socio-économiques influencent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D043326?mesh_terms=Lymph+Node+Excision&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en glucan 1,3-beta-glucosidase ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par des tests enzymatiques et des analyses génétiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer l'activité de l'enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques spécifiques mesurent l'activité de la glucan 1,3-beta-glucosidase dans les échantillons." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue, des douleurs abdominales ou des troubles digestifs peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques associés à cette enzyme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de glucanes dans le sang peuvent servir de marqueurs biologiques." } }, { "@type": "Question", "name": "Comment les tests génétiques aident-ils au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils identifient des mutations spécifiques dans le gène codant pour l'enzyme, confirmant le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en glucan 1,3-beta-glucosidase ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleurs abdominales, et troubles de la digestion." } }, { "@type": "Question", "name": "La déficience peut-elle causer des problèmes immunitaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience peut affecter le système immunitaire, augmentant la susceptibilité aux infections." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir, bien que moins fréquents, comme des maux de tête." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de la gravité de la déficience." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais la déficience elle-même est généralement permanente." } }, { "@type": "Question", "name": "Peut-on prévenir la déficience en glucan 1,3-beta-glucosidase ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La déficience est généralement génétique, donc la prévention n'est pas possible." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les symptômes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications alimentaires et un suivi médical régulier peuvent aider à gérer les symptômes." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les porteurs et informer sur les risques." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la maladie et ses symptômes est cruciale pour une gestion efficace." } }, { "@type": "Question", "name": "Les conseils diététiques peuvent-ils prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conseils diététiques appropriés peuvent aider à prévenir des complications digestives." } }, { "@type": "Question", "name": "Quels traitements existent pour la déficience en glucan 1,3-beta-glucosidase ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments enzymatiques et des modifications alimentaires." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à gérer les symptômes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments peuvent être prescrits pour soulager les symptômes digestifs et la douleur." } }, { "@type": "Question", "name": "Y a-t-il des thérapies alternatives recommandées ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies alternatives, comme la phytothérapie, peuvent être envisagées, mais avec prudence." } }, { "@type": "Question", "name": "La diététique joue-t-elle un rôle dans le traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation adaptée peut aider à réduire les symptômes et améliorer la qualité de vie." } }, { "@type": "Question", "name": "Des traitements expérimentaux sont-ils disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des traitements expérimentaux, mais ils ne sont pas encore largement disponibles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications digestives, immunitaires et neurologiques peuvent se développer." } }, { "@type": "Question", "name": "La déficience peut-elle entraîner des infections fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience en glucan 1,3-beta-glucosidase peut augmenter le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des complications à long terme peuvent inclure des troubles digestifs chroniques et des infections récurrentes." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par une gestion proactive des symptômes." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque de déficience ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer l'apparition des symptômes, mais la déficience est généralement génétique." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'y a pas de preuves solides que les facteurs environnementaux influencent ce risque." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents médicaux de troubles digestifs peuvent augmenter la suspicion de déficience." } }, { "@type": "Question", "name": "Les facteurs socio-économiques influencent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs socio-économiques peuvent affecter l'accès aux soins, mais pas directement le risque génétique." } } ] } ] }

Sources (7946 au total)

Radiation, Lymph Node Dissection, or Both: Management of Lymph Node Micrometastases from Merkel Cell Carcinoma.

Regional lymph node micrometastases from Merkel cell carcinoma (MCC) can be treated with completion lymph node dissection (CLND) and/or radiation therapy (RT). It is unclear how these options compare ... This retrospective cohort study used data from years 2012-2019 of the National Cancer Database. Patients with MCC and clinically negative, but pathologically positive, lymph node metastases who receiv... A total of 962 patients were included [median (interquartile range) age, 74 (67-80) years, 662 (68.8%) male patients, 926 (96.3%) white patients]. The majority (63%, n = 606) had a CLND only, while 18... The usage of RT for nodal micrometastasis in MCC is increasing as compared with CLND. This strategy appears to be safe, with no significant difference in survival outcomes....

Clinical outcomes of neoadjuvant therapy followed by selective inguinal lymph node dissection and total mesorectal excision for metastasized low rectal cancer.

Rectal or anal canal adenocarcinoma with inguinal lymph node metastasis (ILNM) is rare and is associated with poor prognostic outcomes. This study aimed to elucidate the clinical significance of neoad... This study enrolled 15 consecutive patients who underwent neoadjuvant therapy and curative resection for rectal or anal canal adenocarcinoma with clinically suspected ILNM between 2005 and 2019 at a s... Out of the15 patients, 11 were treated with neoadjuvant chemoradiation, three with chemotherapy, and one with chemoradiation followed by chemotherapy. Fluorodeoxyglucose (FDG)-positron emission tomogr... In patients with rectal or anal canal adenocarcinoma associated with clinical ILNM, radical resection with neoadjuvant therapy provides a good long-term survival....

Robotic versus laparoscopic total mesorectal excision with lateral lymph node dissection for advanced rectal cancer: A systematic review and meta-analysis.

Lateral pelvic node dissection (LPND) poses significant technical challenges. Despite the advent of robotic surgery, determining the optimal minimally invasive approach remains a topic of debate. This... This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 and AMSTAR 2 (Assessing the Methodological Quality of Systematic Revie... Six eligible studies involving 652 patients (316 and 336 in the R-LPND and L-LPND groups, respectively) were retrieved. The robotic approach demonstrated favourable outcomes compared with the laparosc... In summary, the robotic approach is a safe and feasible alternative for Total Mesorectal Excision (TME) with LPND in advanced rectal cancer. Notably, it is associated with lower morbidity, particularl...

Inguinal Lymph-Node Ratio (LNR) as a predictor of Pelvic Lymph-Node Metastasis in squamous cell carcinoma of penis.

To determine the predictors of pelvic lymph-node metastasis in cases of squamous cell carcinoma (SCC) of penis.... Data was retrospectively collected from 267 cases of SCC penis that presented at our institute between 2009 and 2019. Univariate and multivariate logistic regression models were used to identify indep... Pelvic Lymph-Node Metastasis (PLNM) was pathologically detected in 56 groins (29.2%). A cut-off of 0.25 was calculated for LNR based on ROC. LNR >0.25 (p = 0.003), ENE (p = 0.037), and LVI (p = 0.043)... LNR >0.25, LVI and, ENE are independent predictors of PLNM. The discriminative ability of LNR was better than PLN. PLND could be avoided if no risk factors are present....

Factors Associated With Lymph Node Yield and Effects of Lymph Node Density on Survival of Patients With Pulmonary Sarcomatoid Carcinoma.

The objective of this study was to identify factors associated with lymph node yield (LNY) during surgeries for pulmonary sarcomatoid carcinoma (PSC) and to determine effects of lymph node density (LN... The SEER Research Plus database was searched for data on patients with PSC from 1988 to 2018. Poisson regression was used of all patients with PSC to identify relevant factors associated with LNY. Uni... There were 545 eligible patients in the study sample, 175 of which were LN-positive. These patients had significantly lower 5-year OS than those with no positive LNs ( P <0.001). Poisson regression an... Patients with PSC with high LND experienced worse outcomes than those with low LND. Further risk stratification of patients with PSC may help to improve survival benefits based on prognostic indicator...

Impact of lymph node ratio and number of lymph node metastases on survival and recurrence in laryngeal squamous cell carcinoma.

The aim of this study is to assess the impact of lymph node ratio (LNR) and number of positive lymph nodes (NPLN) on mortality and recurrence rates in patients with laryngeal squamous cell carcinoma.... We conducted a retrospective multicenter international study involving 24 Otorhinolaryngology-Head and Neck Surgery divisions. Disease-specific survival (DSS) and disease-free survival (DFS) were eval... 2507 patients met the inclusion criteria. DSS and DFS were significantly different in the groups of patients stratified according to LNR and NPLN. The 5-year DSS and DFS based on LNR and NPLN demonstr... Our data demonstrate the potential prognostic value of NPLN and LNR in laryngeal squamous cell carcinoma....

Metastatic lymph node ratio as an important prognostic factor in advanced gallbladder carcinoma with at least 6 lymph nodes retrieved.

The metastatic lymph node (LN) ratio (LNR) has shown to be an important prognostic factor in various gastrointestinal malignancies. Nevertheless, the prognostic significance of LNR in gallbladder carc... From January 2007 to January 2018, 144 advanced GBC patients (T2-4 stages) who underwent curative surgery with at least 6 LNs retrieved were enrolled. Receiver operating characteristic (ROC) curve was... The optimal cut-off point for LNR was 0.28 according to the ROC curve. LNR>0.28 was associated with higher rate of D2 LN dissection (P=0.004) and higher tumor stages (P<0.001). Extent of liver resecti... LNR is correlated to advanced GBC prognosis and is a potential prognostic factor for advanced GBC with at least 6 LNs retrieved....

RATIO OF METASTATIC LYMPH NODES VS. RESECTED LYMPH NODES (N-RATIO) HAS PROGNOSTIC IMPLICATIONS IN GASTRIC CANCER.

Lymph node status is vital for gastric cancer (GC) prognosis, but the conventional pN stage may be limited by variations in lymphadenectomy and stage migration. The N-Ratio, which assesses the ratio o... To assess N-Ratios prognostic value in GC, particularly in patients with <25 resected lymph nodes.... Patients who underwent gastrectomy with curative intent for GC were retrospectively evaluated. The N-Ratio categories were determined using the ROC curve method, and the area under the curve (AUC) was... A total of 561 GC patients were included in the study, 57% had pN+ status, and 17.5% had <25 resected lymph nodes. N-Ratio, with a mean of 0.12, predicted survival with 74% accuracy (AUC=0.74; 95%CI 0... N-Ratio influenced survival in GC patients, especially in advanced lymph node disease (N-Ratio 3). Considering that N-Ratio does not impact pN0 cases, individualized prognosis assessment is essential ...

N1 lymph node detection in lymph node harvesting in non-small cell lung cancer: Formaldehyde exposure is a drawback?

This study aimed to evaluate the effect of lymph node dissection method on staging results, diagnosis of tumor metastasis in single or multiple N1 lymph nodes and survival rates in patients with non-s... Patients with NSCLC who underwent anatomic resection between September 2014 and October 2019 were examined prospectively. All patients with similar clinico-demographic characteristics were randomly as... There were no significant differences in N1 lymph node positivity between the two groups (p = 0.482). On average 9.08 lymph node sampling was performed in the surgical group and 2.39 in the pathology ... It is easier to detect lymph node involvement without introducing formaldehyde into the sample. We recommend that N1 lymph node dissection be performed on fresh specimens to detect more lymph node inv...